Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 2:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2521–2544 of 3,919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Prostate Cancer Clear all

Conditions: Castration-resistant Prostate Cancer
Interventions: AR Blockade, Carotuximab; Drug
Lead sponsor: Edwin Posadas, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 3
States / cities: Duarte, California • Los Angeles, California • Salt Lake City, Utah

Conditions: Prostate Cancer, Prostate Cancer Recurrent
Interventions: Metformin Hydrochloride Extended Release 750mg; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Mineola, New York

Conditions: Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced or Metastatic Solid Tumors, Prostate Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Intrahepatic Cholangiocarcinoma, Squamous Cell Anal Cancer, Squamous Cell Penile Carcinoma, Squamous Cell Vulvar Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma
Interventions: XmAb®22841, Pembrolizumab (Keytruda®); Biological
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 28
States / cities: Encinitas, California • La Jolla, California • Los Angeles, California + 15 more

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Social Determinants of Health, Breast Cancer, Prostate Cancer, Health Equity, Disparities
Interventions: Community Health Worker support; Behavioral
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 506 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Prostate Cancer
Interventions: Relugolix; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostatic Neoplasms
Interventions: Radium-223 dichloride (Xofigo, BAY88-8223), Abiraterone acetate, Prednisone, Enzalutamide; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 19
States / cities: Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 16 more

Conditions: Prostate Cancer
Interventions: Observation of transponder stability; Other
Lead sponsor: Varian, a Siemens Healthineers Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Scottsdale, Arizona • St Louis, Missouri

Conditions: Prostatic Neoplasms, Castration-Resistant
Interventions: Enzalutamide, Abiraterone acetate; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 5,506 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: bicalutamide, goserelin acetate, assessment of therapy complications, quality-of-life assessment, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: Radiotherapy, Samarium 153; Radiation · Drug
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 29
States / cities: Phoenix, Arizona • Auburn, California • Cameron Park, California + 22 more

Conditions: Kidney Cancer, Prostate Cancer
Interventions: Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution, 0.9% Sodium Chloride Injection; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Prostate Cancer
Interventions: Help with decision making on prostate cancer treatment; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 50 Years to 80 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2001
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prostate Adenocarcinoma
Interventions: 68Ga-RM2, Magnetic Resonance Imaging, Positron Emission Tomography; Drug · Procedure
Lead sponsor: Andrei Iagaru; Other
Eligibility: 18 Years and older · Male only
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Prostate Cancer
Interventions: Docetaxel, Bevacizumab, ADT, Bicalutamide; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 3
States / cities: Baltimore, Maryland • Boston, Massachusetts

Conditions: Castration-resistant Prostate Cancer
Interventions: Crizotinib, Enzalutamide; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Localized Prostate Cancer
Interventions: Aquablation Therapy, Active Surveillance; Device · Other
Lead sponsor: PROCEPT BioRobotics; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2038
U.S. locations: 27
States / cities: Chandler, Arizona • Los Angeles, California • Murrieta, California + 23 more

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 8
States / cities: Washington D.C., District of Columbia • Chapel Hill, North Carolina • High Point, North Carolina + 4 more

Conditions: Prostatic Neoplasms
Interventions: DVD Decision Aid, Written decision aid; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older · Male only
Enrollment: 564 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Prostate Cancer
Interventions: Use of the online "Talk to Nathan about Prostate Cancer" decision aid, Use of a standard prostate cancer screening decision aid, Use of standard prostate cancer education materials; Behavioral
Lead sponsor: David Siegel; Federal
Eligibility: 55 Years to 69 Years · Male only
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 4
States / cities: East Northport, New York • Charlotte, North Carolina • Raleigh, North Carolina + 1 more

Conditions: Breast Cancer, Liver Cancer, Prostate Cancer
Interventions: Clinical trial match-list, Match-list intervention; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 21 Years and older
Enrollment: 585 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: New York, New York • The Bronx, New York

Conditions: Localized Prostate Cancer, BPH (Benign Prostatic Hyperplasia), Prostate Cancer; Benign Prostatic Hyperplasia
Interventions: High Intensity Focused Ultrasound; Device
Lead sponsor: Sonablate; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2035
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Breast Carcinoma, Colorectal Carcinoma, Lung Carcinoma, Malignant Solid Neoplasm, Ovarian Carcinoma, Pancreatic Carcinoma, Prostate Carcinoma
Interventions: Best Practice, Educational Intervention, Genomic Profile, Survey Administration; Other · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Breast Cancer, Multiple Myeloma, Prostate Cancer
Interventions: zoledronic acid; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 7
States / cities: Stockton, California • Kissimmee, Florida • Las Vegas, Nevada + 3 more

Search by objective public record fields.

Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Canc

Metformin Prostate Cancer Adjuvant Trial

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Improving Cancer Foci Detection in Prostate Cancer Using Multiparametric MRI/MRS

Social Risk Factors and Discrimination in Cancer Survivorship

Description of Relugolix Use in Patients With Prostate Cancer Within the VHA

A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)

CMT-07-08: The PROstate Bed Evaluation Study

Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)

Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer

Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer

Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery

Treatment Decision Intervention for Veterans With Prostate Cancer

68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer

Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer

Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer

WATER IV PCa (AS Sub-study)

Cardiovascular Risk and Preventive Care in Prostate Cancer Patients Receiving Radiation and Hormone Therapy

Testing Decision Aids About Early Stage Prostate Cancer

Evaluation of an Online Prostate Cancer Screening Decision Aid

Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials

Sonablate HIFU International Registry for PC & BPH Patients

HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics

Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions